European Heart Journal vs Annals of Oncology: Which Journal Should You Choose?

EHJ asks whether the paper matters to cardiologists. Annals asks whether the paper matters to oncologists.

That sounds obvious, but it's exactly where many cardio-oncology papers get misrouted.

If the manuscript depends on ESC relevance, cardiovascular risk frameworks, cardiotoxicity surveillance, imaging interpretation, or heart-failure logic to show its consequence, EHJ usually becomes the better home. If the manuscript depends on oncology treatment strategy, biomarker selection, trial interpretation, or cancer patient management to show its value, Annals usually becomes the better home.

EHJ wins when the cardio-oncology manuscript is fundamentally a cardiovascular paper.

That usually means:

• cardiotoxicity or cardiovascular risk from cancer therapy
• heart-failure, arrhythmia, imaging, or prevention work in cancer populations
• registry or observational data that cardiologists will actually act on
• a paper that gets stronger when framed inside cardiovascular guidelines and ESC relevance

EHJ's editorial guidance are consistent that the journal wants broad field consequence across cardiology, not just a narrow subspecialty signal.

Annals wins when the manuscript is fundamentally an oncology paper.

That includes:

• studies about treatment strategy where cardiac safety is a major but still oncology-facing issue
• biomarker or translational work that matters mainly for oncology decisions
• cancer trial papers where cardiovascular outcomes are part of the broader clinical oncology story
• oncology-facing supportive care or survivorship work that still belongs inside cancer medicine

The Annals source set repeatedly emphasizes broad clinical or translational oncology consequence and a complete evidence package.

EHJ submission's editorial guidance pushes authors to connect findings to ESC guidelines, European cardiovascular practice, registries, and field-level consequence. That's a clue that cardio-oncology work belongs there only when the cardiac implications are the real headline.

Annals's editorial guidance stresses multicenter validation, stronger efficacy endpoints, and translational logic. That favors oncology-led studies with broad treatment or biomarker consequences.

A paper can remain anchored in cardiology terms there, as long as the consequence is broad enough inside the field. Annals is less interested in carrying a paper whose main burden of explanation is cardiovascular.

If the manuscript is fundamentally about cancer therapy, oncology decision-making, or patient management, oncology-native framing isn't a weakness there. It's expected.

• the paper is fundamentally about cardiovascular consequence
• cardiologists are the main audience
• ESC-facing relevance, imaging, prevention, or cardiovascular outcomes are central
• the manuscript becomes stronger when written for cardiology readers

That's the EHJ lane.

• the paper is fundamentally about oncology consequence
• oncologists are the main audience
• treatment strategy, biomarker use, or broad oncology practice is central
• the manuscript becomes stronger when written for oncology readers

That's the Annals lane.

This isn't a simple prestige cascade.

A paper rejected by EHJ does not automatically become an Annals paper, and vice versa.

The cascade only works when the first submission failed because the journal saw the paper as belonging more naturally to the other specialty.

That can happen when:

• the manuscript sits at the border between oncology and cardiology
• the methods are strong
• the question is important to both fields
• the first journal judged that the primary readership was actually the other specialty

It doesn't work when the manuscript is simply too narrow or too weak for either field-leading journal.

If the cardiovascular consequence feels secondary to the cancer story, EHJ gets harder quickly.

If the main practical readers are cardiologists and the cancer story is mostly context, the oncology case weakens quickly.

The journal's editorial guidelines are clear that the journal wants broad cardiovascular importance, not only good cardio-oncology mechanics.

Single-center, early, or weakly validated oncology stories struggle there even when the cardio-oncology angle is interesting.

These are usually cleaner EHJ papers if the purpose is to change cardiology care or monitoring strategy.

These are often cleaner Annals papers if the main audience is oncology and the cardiac analysis supports treatment choices.

This category can go either way. If the paper is mainly about cardiovascular risk management, EHJ becomes more plausible. If it's mainly about oncology survivorship strategy, Annals usually wins.

The key question is whether the field that needs to act first is cardiology or oncology. That usually tells you the better target.

A strong EHJ first page makes the cardiovascular consequence obvious immediately. The reader should understand why cardiologists need this paper now.

A strong Annals first page makes the oncology consequence obvious immediately. The reader should understand why oncologists need this paper now.

If you need both first pages at once, the manuscript may still be too undecided.

Ask which sentence fits the manuscript better:

• "this changes what cardiologists should do or think" points toward European Heart Journal
• "this changes what oncologists should do or think" points toward Annals of Oncology

That sentence is often the most honest triage tool you have.

For cardio-oncology work, the wrong readership can flatten the paper's value. A study that's excellent for cardiologists can look oddly secondary to oncologists. A study that's excellent for oncologists can look only indirectly actionable to cardiologists.

This is why audience clarity matters more here than in many other journal-vs-journal decisions.

Send to European Heart Journal first if:

1. the paper is fundamentally cardiovascular
2. cardiologists are the readers who most need it
3. ESC-facing relevance or cardiovascular management is central
4. the paper gets stronger when written for cardiology

Send to Annals of Oncology first if:

1. the paper is fundamentally oncology-led
2. oncologists are the readers who most need it
3. treatment strategy or oncology management is central
4. the paper gets stronger when written for oncology